Etiologics is an innovative drug discovery company that, unlike most new companies in this sector, has a balanced portfolio of ethylnitrosourea (ENU) technology, animal models of disease, in vitro cell function models, and expertise in drug discovery, which spans the whole drug discovery process. The aim of the company is to identify and develop novel effective therapies for respiratory and metabolic diseases where there is a high unmet medical need. Etiologics also offers partners access to its ENU technology and/or preclinical respiratory models/expertise to enable them to identify/validate new targets and enhance the value of in-house programs.